Treatment with nontoxic monophosphoryl lipid A increased the magnitude of the immunoglobulin M (IgM) antibody response to type III pneumococcal polysaccharide in young (2-to 4-week-old) mice. This was accompanied by the appearance of significant numbers of IgGl-and IgG3-secreting antibody-forming cells in 4-week-old mice. These findings indicate that monophosphoryl lipid A can be used as an adjuvant to improve the immunogenicity of poorly immunogenic antigens in young, immunologically immature animals.
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The failure of infants or young children to make an adequate antibody response to bacterial capsular polysaccharides is considered to be a major factor in the prevalence of various bacterial infections in certain age groups (10, 16, 20, 24, 26) . Consequently, many attempts have been made to improve the immunogenicity of these antigens in order to increase their effectiveness for use as vaccines (9, 11, 18, 21, 25, 28) . Detailed studies on the ontogeny of the antibody response to type III pneumococcal polysaccharide (SSS-III) revealed that the inhibitory effects of thymus-derived (T) suppressor cells are predominant in young mice and that such cells may play an important role in determining the ease with which immunological tolerance is induced in neonates (22) . Since treatment with nontoxic monophosphoryl lipid A (MPL) has been shown to inactivate suppressor T cells without altering other T-cell functions (2), we examine in the present work whether treatment with MPL might increase the capacity of young mice to make an antibody response to this antigen.
MATERIALS AND METHODS
Mice. BALB/cAnN mice, 2 to 4 weeks of age (±3 days), were obtained from the Veterinary Resources Branch, Division of Research Services, National Institutes of Health, Bethesda, Md.
Antigen and immunization procedure. The immunological properties of the SSS-III preparation used have been described (1, 3-7). Mice were given a single intraperitoneal (i.p.) injection of an optimally immunogenic dose of SSS-III in 0.1 ml of saline. The doses used were found to be optimal in previous studies using BALB/cAnN mice of different ages immunized with the same preparation of SSS-III (22 blocking method (23) by using optimal amounts of affinitypurified goat anti-mouse IgM blocking antiserum and isotype-specific rabbit anti-mouse immunoglobulin facilitating antisera purchased from Zymed Laboratories, Inc., South San Francisco, Calif. Corrections were made (by subtraction) for numbers of background sheep erythrocytespecific PFC found so that only values for SSS-III-specific PFC were considered. The values obtained (SSS-III-specific PFC per spleen), which are log-normally distributed (17) , are expressed as the geometric mean (antilog) of the log1o number of PFC per spleen for groups of similarly treated mice. This provides a valid measure of the magnitude of the total antibody response, since SSS-III-specific PFC are detected only in the spleens of immunized mice (1, 3, 19).
Student's t test was used to assess the significance of the differences observed. Differences were considered to be significant when probability (P) values <0.05 were obtained.
MPL. MPL (average molecular weight, 1,718) derived from a polysaccharide-deficient heptoseless Re mutant of Salmonella typhimurium G30/C21 was obtained from RibilmmunoChem Research, Inc., Hamilton, Mont. Its immunological properties, as well as the method by which it was reconstituted for use, have been described (2). Mice were given a single injection (i.p.) of MPL in 0.1 ml of saline 2 days after immunization with SSS-III. Mice immunized with SSS-III usually make antibody only of the IgM class; this is true for 4-week-old mice (Table 2) as well as for adult (8-to 10-week-old) mice (1, 5). Treatment with MPL causes not only an increase in numbers of IgM-secreting SSS-III-specific PFC, but also the appearance of significant (P <0.001) numbers of IgGl-and IgG3-secreting SSS-Ill-specific PFC (Table 2) ; similar results were obtained in several other experiments by using 4-and 8-week-old mice (data not shown). MPL had no effect upon numbers of IgG2a-and IgG2b-secreting SSS-III-specific PFC (Table 2) .
Detailed studies on the ontogeny of the antibody response to SSS-Ill in BALB/cAnN mice showed that the capacity of B cells to respond to SSS-III, as well as the functional activity of both amplifier T cells (TA) and T., increases at different rates with age (22 It has been established that antibody specific for the type-specific capsular polysaccharides of pneumococci confers protective immunity against virulent Streptococcus pneumoniae (12-15) ; however, in addition to the increased IgM antibody response, the appearance of significant amounts of IgGl and IgG3 antibody, which are not usually made in young mice immunized with SSS-III, might contribute in another way to the development of greater protective immunity in young mice. Because the half-life of IgGl and IgG3 antibody (6 to 8 days) is longer than that of IgM antibody (2 days [27] ), the synthesis of these isotypes would prolong the duration of protective immunity, perhaps until such time as the capacity to make an antibody response is more fully developed. 
